Altiratinib

Overview

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC 50 s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET , TIE2 , VEGFR2 , FLT3 , Trk1 , Trk2 , and Trk3 respectively.

Application

Products | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > c-Met/HGFR | Products > Signaling Pathways > FLT3 | Products > Signaling Pathways > Trk Receptor

Product Information

• Catalog No.: HY-B0791
• CAS No.: 1345847-93-9
• Molecular Formula: C26H21F3N4O4
• Molecular Weight: 510.46
• Purity: 99.29%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (4.90 mM); Clear solution
• Availability: In-stock

Source

Original product source